These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
515 related items for PubMed ID: 16689976
1. Parathyroid growth and suppression in renal failure. Lewin E, Huan J, Olgaard K. Semin Dial; 2006; 19(3):238-45. PubMed ID: 16689976 [Abstract] [Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L. Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [Abstract] [Full Text] [Related]
3. Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate. Canalejo A, Canalejo R, Rodriguez ME, Martinez-Moreno JM, Felsenfeld AJ, Rodríguez M, Almaden Y. Nephrol Dial Transplant; 2010 Apr; 25(4):1087-97. PubMed ID: 19934096 [Abstract] [Full Text] [Related]
4. Influence of parathyroid mass on the regulation of PTH secretion. Lewin E, Olgaard K. Kidney Int Suppl; 2006 Jul; (102):S16-21. PubMed ID: 16810305 [Abstract] [Full Text] [Related]
5. Pathogenesis of parathyroid hyperplasia in renal failure. Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A. J Nephrol; 2005 Jul; 18(1):5-8. PubMed ID: 15772917 [Abstract] [Full Text] [Related]
6. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M. Ther Apher Dial; 2005 Aug; 9 Suppl 1():S27-34. PubMed ID: 16109139 [Abstract] [Full Text] [Related]
7. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. Cañadillas S, Canalejo A, Santamaría R, Rodríguez ME, Estepa JC, Martín-Malo A, Bravo J, Ramos B, Aguilera-Tejero E, Rodríguez M, Almadén Y. J Am Soc Nephrol; 2005 Jul; 16(7):2190-7. PubMed ID: 15888568 [Abstract] [Full Text] [Related]
8. 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. Dusso A, Cozzolino M, Lu Y, Sato T, Slatopolsky E. J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):507-11. PubMed ID: 15225829 [Abstract] [Full Text] [Related]
9. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis. Martin LN, Kayath MJ, Vieira JG, Nosé-Alberti V. Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048 [Abstract] [Full Text] [Related]
10. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Brown AJ, Slatopolsky E. Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840 [Abstract] [Full Text] [Related]
11. Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice. Arcidiacono MV, Yang J, Fernandez E, Dusso A. Nephrol Dial Transplant; 2015 Mar; 30(3):434-40. PubMed ID: 25324357 [Abstract] [Full Text] [Related]
12. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients. Wang X, Sun B, Zhou F, Hu J, Yu X, Peng T. Chin Med J (Engl); 2001 Apr; 114(4):410-4. PubMed ID: 11780466 [Abstract] [Full Text] [Related]
13. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A. Semin Dial; 2005 Apr; 18(3):226-38. PubMed ID: 15934970 [Abstract] [Full Text] [Related]
14. Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K. J Am Soc Nephrol; 2002 Aug; 13(8):2110-6. PubMed ID: 12138143 [Abstract] [Full Text] [Related]
15. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease]. Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627 [Abstract] [Full Text] [Related]
16. The genetic background of uremic secondary hyperparathyroidism. Aucella F, Morrone L, Stallone C, Gesualdo L. J Nephrol; 2005 Sep; 18(5):537-47. PubMed ID: 16299679 [Abstract] [Full Text] [Related]
17. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Nephrol Dial Transplant; 2006 Mar; 21(3):634-43. PubMed ID: 16169864 [Abstract] [Full Text] [Related]
18. Effect of endothelin receptor antagonist on parathyroid gland growth, PTH values and cell proliferation in azotemic rats. Jara A, von Höveling A, Jara X, Burgos ME, Valdivieso A, Mezzano S, Felsenfeld AJ. Nephrol Dial Transplant; 2006 Apr; 21(4):917-23. PubMed ID: 16431896 [Abstract] [Full Text] [Related]
19. Roles of calcium-sensing receptor and vitamin d receptor in the pathophysiology of secondary hyperparathyroidism. McCann LM, Beto J. J Ren Nutr; 2010 May; 20(3):141-50. PubMed ID: 20303786 [Abstract] [Full Text] [Related]
20. [Pathogenesis of secondary hyperparathyroidism and renal bone disease]. Ito H, Kinugasa E. Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032 [Abstract] [Full Text] [Related] Page: [Next] [New Search]